Tag Archives for U.S. Department of Justice

Fraud Schemes Targeting Older Adults: Senate Aging Committee Sounds Alarm

Published in RINewsToday on July 21, 2025

“Congratulations! We are pleased to inform you that you are one of our lucky winners,” read the letter.

The official-looking correspondence—purportedly from the desk of the Vice President, International Promotions/Prize Award Department of Publishers Clearing House (PCH)—continued:

“On behalf of the members and staff of PCH, the Association of North America Lottery, and Provincial Sweepstakes, we sincerely congratulate you on your grand prize winnings of $750,000… Please contact your claims agent to arrange method of payment.”

Enclosed was a check, appearing legitimate, allegedly issued by Northern Fairfield Insurance (NFI) of Danbury, Connecticut, from a Webster Bank account, in the amount of $9,700.65.

According to the letter, the check was intended to help cover taxes, handling, and processing fees related to the prize.

Northern Fairfield Insurance, established in 1998, is a small firm with just three employees, including its owner, Jim Ostrove. Nearly two weeks ago, Ostrove began receiving calls—mine among them—asking whether the PCH letter and enclosed check were legitimate.

“The volume has tapered off by the day,” he admits, noting that “we’re no longer receiving any calls.”

A quick call to NFI confirmed my suspicions: the letter, marked “Confidential,” was a scam. In conversation with Ostrove, he said, “I felt violated and angry.”

Concerned, Ostrove contacted Webster Bank—the financial institution listed on the counterfeit check—to confirm that no account had been set up in his company’s name. The bank quickly verified this, noting that the check’s routing number was invalid and had no connection to a legitimate account. “Looking closely at the PCH check, I also realized that the name of my insurance company was misspelled,” Ostrove added.

Ostrove says the bank’s fraud unit was very helpful and confirmed the check was fake. His concerns about any potential financial fallout for his business were eased, he says.

Although Ostrove filed a police report, he had no real expectation that the scammers would be caught. “I just wanted the report on file in case someone came forward about the reward and tried to hold me financially responsible,” he said.

“My report made it very clear that I was a victim of fraud,” he emphasized.

According to the Federal Trade Commission, victims reported nearly $350 million in losses to prize, sweepstakes, and lottery-related scams in 2024.

Like me, the Better Business Bureau estimates that tens of thousands of individuals will receive similar scam mailings in 2025—complete with fake prize notifications, counterfeit checks, and fraudulent requests for payment or personal information. The actual number of victims may be much higher, as many incidents go unreported.

Senate Aging Committee Puts a Spotlight on Scams and Financial Exploitation

On Feb. 12, 2016, the U.S. Senate Special Committee on Aging announced the publication of its first full-year “Fraud Book,” Protecting Older Americans Against Fraud, covering the period from January 1 to December 31, 2015. These annual reports aim to raise awareness about the growing number of fraud schemes targeting older Americans and provide specific recommendations to combat them.

The latest, published just recently, is a 40-page multi-language annual report, Age of Fraud: Scams Facing Our Nation’s Seniors (Report No. 119-35 of the 119th Congress), and was released on July 10, 2025. It highlights the many forms of fraud—including grandparent scams, tech support fraud, financial service scams, travel and timeshare fraud, romance scams, and government impersonation schemes.

“These schemes often target emotional vulnerabilities, particularly among seniors facing loneliness, isolation, or depression,” note Chairman Rick Scott (R-Florida) and Ranking Member Kirsten Gillibrand (D-New York) in a statement announcing the newly released report.

The 2025 bipartisan report outlines the growing financial threats facing aging Americans and ways for seniors to identify red flags that provide warnings of scams, suggests practical tips on how to protect themselves, and how to report scams. This year’s edition underscores the alarming rise in sophisticated schemes, particularly those utilizing artificial intelligence (AI). In 2024 alone, fraud and scams cost seniors over $4.8 billion, with those aged 50–59 losing an additional $2.5 billion.

“Across our nation, older Americans are being targeted every day by increasingly sophisticated scams that rob them not only of their hard-earned savings but also of their security and peace of mind. These attacks are personal, and they are unacceptable,” says Scott, stressing that fighting fraud against older Americans will remain a top priority for the Committee.

“Through critical initiatives like National Slam the Scam Day and our toll-free Fraud Hotline, we are expanding access to education, prevention tools, and direct support to empower families to recognize fraud and respond quickly,” he says.

“This report shines a direct light on the scale and severity of the threat we’re facing, and we must be united in our determination to stay vigilant, informed, and proactive in defending our seniors,” adds Scott.

Gillibrand adds, “We must do everything we can to prevent and fight back against these scams, and that starts with monitoring fraud whenever and wherever it occurs. As Ranking Member of the Senate Aging Committee, I’m committed to continuing the fight against fraud, and I hope this Fraud Book is a valuable resource for our aging communities.”

The report serves as a significant wake-up call to Congress. Fraud continues to skyrocket, notes the Committee. Citing FBI data, 2024 was a record year for losses reported to the Internet Crime Complaint Center, totaling a staggering $16.6 billion. There were 859,532 complaints that year—and over 4.2 million complaints over the past five years.

The report also emphasizes that fraud targeting older adults is growing in both complexity and financial impact, making enhanced awareness, education, and robust support systems more critical than ever.

 According to the FBI, from 2023 to 2024:

  • Overall losses increased 33%, mostly due to fraud.
  • Average loss for those age 60 and older rose to $83,000.
  • Reports for this age group increased by 43%.
  • Cryptocurrency-related losses rose by 66%.
  • Complaints involving cryptocurrency kiosks increased by 99%.

To safeguard aging Americans from fraud, scams, and financial exploitation, the Senate Aging Committee has led two bipartisan efforts: one resolution designating March 6, 2025, as National Slam the Scam Day to raise awareness and educate the public about fraud prevention, and another recognizing May 2025 as Older Americans Month. Both efforts aim to inform and protect older adults while reinforcing the committee’s commitment to combating fraud through public education, legislative action, and advocacy for stronger safeguards—ensuring seniors can enjoy their golden years with greater security and peace of mind.

From the Ocean State

According to the 2025 Fraud Report, the Federal Trade Commission reported 11,776 complaints were filed in Rhode Island in 2024.

“Our team tracks patterns of scams reported to us throughout the year,” says Timothy M. Rondeau, Communications Director for the Rhode Island Office of the Attorney General. “This year, we’ve continued to see a wide range of fraudulent actors deceiving Rhode Islanders through romance scams, imposter scams, and scams involving cryptocurrency.”

According to Rondeau, while new scams aren’t necessarily emerging, the tools and methods used are evolving. “AI tools are increasingly used in imposter and romance scams, where AI-generated voices and videos deceive and manipulate victims,” he explains. “While we can’t always confirm AI involvement in each case, we know the use of AI makes it much harder—especially for older adults—to distinguish between real and fraudulent interactions.”

For more information about common scams or to file a complaint, Rhode Islanders can visit: riag.ri.gov/scams

If you or someone you know has been a victim—or suspects they’ve been targeted—please call the Senate Aging Committee’s Fraud Hotline at 1-855-303-9470 (open weekdays from 9 a.m. to 5 p.m. Eastern Time). If you’d like a member of the committee’s team to return your inquiry, please include your phone number in the web form.

Go here to read the Senate Aging Committees 2025 Fraud Report,

The US Dept. of Justice released this information in recognition of Elder Abuse Awareness Day – The Justice Department Highlights Enforcement Efforts Protecting Older Americans from Transnational Fraud Schemes in Recognition of 2025 World Elder Abuse Awareness Day contains specific information on each type of fraud and what the US Government is doing to shut it down.

AARP offers  Tips on Protecting Yourself Against Fraud.

AARP also has a Fraud Watch Network.

Federal Court denies attempt to stop Medicare drug negotiation program

Published in RINewsToday on November 6, 2023

Over two months ago, as supporters of President Biden’s Inflation Reduction Act (IRA) celebrated the one-year anniversary of the passage of the historic legislation, the U.S. Chamber of Commerce, Pharmaceutical Research and Manufacturers of America (PhRMA), along with drugmakers filed multiple lawsuits to block the IRA’s drug price negotiation provisions.  The drug price negotiation program, created by IRA, allows Medicare to use its bargaining power to negotiate the prices of ten prescription drugs for the first time.

The multiple-filed legal suits came weeks before Sept. 1 when the for Centers Medicare & Medicaid Services (CMS) was scheduled to publish a list of the first 10 drugs that would be subjected to negotiations.  These lawsuits argued that the federal price negotiation program was unconstitutional because it violated the First and Fifth Amendments of the U.S. Constitution, as well as the separation of powers clause, by giving the U.S. Department of Health and Human Services (HHS) discretion over a maximum fair price for any given drug selected for negotiation.  These lawsuits also charge that CMS price controls would force drug makers to pull back on developing new drugs, jeopardizing medical breakthroughs for individuals with life-threatening and chronic illnesses. 

Among the nine lawsuits scheduled to go to trial, one was a motion filed on July 12, 2023 by the Chamber and several of its affiliates in Ohio. This motion requested the court to issue a preliminary injunction to halt the Medicare drug negotiation program from implementation. The ruling came before the Oct. 1, 2023 deadline requiring drugmakers whose pharmaceuticals were selected for negotiations to either sign agreements to participate or to face stiff penalties.  

The U.S. Department of Justice opposed the Chamber’s motion, filing a motion to dismiss its case.  On Sept. 15, 2023, the court held oral arguments giving the  Chamber and the DOJ an opportunity to present their legal arguments in greater detail.  

Overcoming a Major Legal Hurdle 

On Friday, September 29, 2023, U.S. District Judge Michael J. Newman for Southern District of Ohio, denied the Chambers request to block implementation of the newly established Medicare drug price negotiation program before the drug price negotiation talks began.  The ruling called on the Chamber to file an amended complaint by Oct. 13, 2023. DOJ would then have until Oct. 27, 2023 to renew its motion to dismiss.

According to Spencer Kimball of CNBC, legal experts say the pharmaceutical industry hopes to see conflicting rules from lawsuits filed in other federal appellate courts to bring this issue to the Supreme Court for final resolution. 

The Willimantic, Connecticut-based Center for Medicare Advocacy (CMA), a nonprofit group pushing for comprehensive Medicare coverage, health equity and quality of health care for seniors and people with disabilities, is encouraged by Judge Newman’s ruling, which assessed the drug manufacturer’s claims “to be weak in the face of clearly established laws.”

According to CMA, the 28-page court order found that the Chamber and other plaintiffs had demonstrated neither likelihood of success on the merits, nor irreparable harm, which are required for a preliminary injunction.  CMS noted that this case cited “clear” law that “participation in Medicare, no matter how vital it may be to a business model, is a completely voluntary choice.” The court also found that the price established by negotiations cannot be considered ‘confiscatory,’ as the Chamber charges or “a violation of due process, because drug manufacturers can opt out of Medicare entirely.”

Newman’s ruling noted that drugmakers are not compelled to sell drugs at the prices established by the Medicare program and that any economic harm, when the negotiated drug prices take effect in 2026, was too speculative to warrant immediate relief, reported CMS.  However, the court did deny the government’s motion to dismiss the lawsuit entirely, saying that more information on whether the plaintiffs have standing to sue would be beneficial and therefore the judge is allowing for limited discovery to clarify issues related to legal standing, after which the government may renew its motion to dismiss, noted the Medicare advocacy group.

With this ruling, Medicare may move forward with its implementation of its drug negotiation program as this case and others continue to proceed. 

Giving their two cents…

At press time, the Chamber did not respond to a request for comment about the court’s ruling.  But health care and aging advocacy groups issued statements expressing their thoughts about the impact of Newman’s ruling. 

“This is the first major blow to Big Pharma in its legal battles to block the drug price negotiation provisions under the Inflation Reduction Act, says Peter Maybarduk, Public Citizen’s director of the Access to Medicines program.

“The Chamber’s lawsuit lacks merit; the court made the right decision not to grant the injunction, which would have caused needless patient suffering and treatment rationing, notes Maybarduk, calling on drugmakers “to drop their lawsuits and drop their prices.”

“Now, drug companies should agree to participate in the negotiation program in good faith. The program is an important first step in ending the exorbitant prices charged to Medicare enrollees,” adds Maybarduk.

Frederick Isasi, Executive Director of Families USA, happily noted that the Medicare drug negotiation program continues, calling the ruling “a big win for seniors and their ability to purchase life-saving medications. The ability to afford medication is a matter of life and death for millions of older adults. That’s why we are fighting this David and Goliath battle – people deserve to pay a fair price for their drugs and Medicare price negotiation is a critical piece of this puzzle. And let’s not forget each drug subject to fair price negotiation is an old drug that millions of people need and doesn’t have competition,” he notes.

“It never ceases to amaze us that – on one hand – Big Pharma can cry poverty by saying that drug negotiations will hurt their bottom line, while recent earnings reports show they are raking in money hand over fist.  We are glad Judge Michael J. Newman, a Trump appointee in Ohio’s Southern District, saw through this hypocrisy by affirming the Biden administration’s power to begin negotiating the prices of 10 medications with drugmakers,” says Dan Adcock, Director of Government Relations and Policy, of the Washington, DC-based National Committee to Preserve Social Security and Medicare. (NCPSSM).

According to NCPSSM, Drug makers made a whopping $493 billion in revenue from ten drugs that are now subject to price negotiations between CMS and the manufacturer, which have accounted for more than $170 billion in gross Medicare spending, according to a report from the nonprofit, Protect Our Care.

“The court’s decision to allow Medicare drug price negotiations to move forward is welcome news, says William Alvarado Rivera, Senior Vice President for Litigation at AARP Foundation. “Pausing Medicare negotiations would have risked billions of dollars in savings for taxpayers – and countless lives. It is unconscionable that Americans face such high prescription drug costs that many people skip taking medication altogether or must ration it,” he said.

“We’re prepared to fight for as long as necessary to ensure big drug companies can’t charge excessive prices at the expense of patients’ health, says Rivera, noting that the new Medicare negotiation law would bring financial and medical relief to millions of older Americans and their families, and put drugs that treat life-threatening and chronic conditions, from cancer to heart disease, within their reach. Rivera says, “It must not be derailed.” 

Congress has put the breaks to the spiraling costs of pharmaceuticals by giving Medicare the authority to negotiate the price of popular drugs with drug makers.  America’s seniors will continue to suffer financial  hardships and many might even lose their lives by not choosing not to take their costly medications if courts rule in favor of drug companies.  Time will tell.   

U.S. Judge Michael J. Newman ruling denying the U.S. Chamber of Commerce’s request for a preliminary injunction, go to https://www.bloomberglaw.com/public/desktop/document/DaytonAreaChamberofCommerceetalvBecerraetalDocketNo323cv00156SDOh/5?doc_id=X3U600KOGG69QHQBPEU24OS1JMO

A listing of drugmaker revenues of the first ten negotiated drugs, go to https://www.protectourcare.org/by-the-numbers-the-ten-costly-drugs-that-are-now-eligible-to-have-lower-prices-negotiated-by-medicare/